DAVA Pharmaceuticals Inc.

Strategic Overview of Spondyloarthropathies: Tapping the Market Opportunity of Niche Immune Diseases.
M2 Presswire; 7/14/2009; 1150 words; ...has announced the addition of Decision Resources, Inc.'s new report "Strategic Overview of Spondyloarthropathies...Myers Squibb - Celgene - Centocor - Daiichi Sankyo - Dava Pharmaceuticals - Eisai - GlaxoSmithKline - Janssen - Johnson &...

Research and Markets: Strategic Overview of Spondyloarthropathies: Tapping the Market Opportunity of Niche Immune Diseases.
Business Wire; 7/14/2009; 1122 words; ...has announced the addition of Decision Resources, Inc.'s new report "Strategic Overview of Spondyloarthropathies...Myers Squibb * Celgene * Centocor * Daiichi Sankyo * Dava Pharmaceuticals * Eisai * GlaxoSmithKline * Janssen * Johnson &...

Impax Reports Improved First Quarter 2009 Revenue and Profit.(Financial report)
Biotech Week; 5/20/2009; 1987 words; ...Impax Laboratories, Inc. (NASDAQ: IPXL...Impax Laboratories, Inc.). Larry Hsu, Ph...across both our Global Pharmaceuticals and Impax Pharmaceuticals divisions to drive...174; (through our DAVA alliance agreement...acquisition of active pharmaceutical ingredients and additional...

Manufacturers index.
MPR Monthly Prescribing Reference; 5/1/2009; 2354 words; ...7704 AstraZeneca Pharmaceuticals (800) 237-8898...Bausch & Lomb Pharmaceuticals (800) 323-0000...1427 Bayer Corp, Pharmaceutical Div. (800) 288...288-8371 Beach Pharmaceuticals (800) 845-8210...Pharmaceuticals, Inc. (888) 5-BERTEK...877) 484-2700 DAVA ...

Poniard Announces Publication of Results of Picoplatin Phase 2 Study in Journal of Clinical Oncology.
PR Newswire; 4/20/2009; 1628 words; ...April 20 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. , a biopharmaceutical company focused on oncology...clinical trial investigator, and chief medical officer of DAVA Oncology. "I am encouraged that picoplatin extended...